Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You have not answered the question(s).
Have theynever(Bertolino and erhlicih/menon) then been allowed to buy, based upon your given definition?
Please explain, specifically, why they can't buy now. Thousands of ceo's/cfo's/cmo's exercise insider transactions frequently.
What makes Erhlich's situation so "special" that he is prohibited from buying or selling?
I’m glad you are so content with this man’s(ceo/cfo) success. It has done wonders for shareholders.
If one was “fortunate enough to invest about a year ago, one would only be down ~85%. If the ceo/cfo adjusted his salary hebe making ~$73,000/year vs $465,000/year.
Don’t forget his 18,000,000 options exercisable at 11 cents/share.
I agree,but not for his concern for other shareholders.
Ha, I agree, LOL.
“Call Art.....”
I’ve tried in the past and again today- same result, no extension for him.
“Really all we can go by is signs coming out of HQ. “
I can’t get a phone pick-up, never mind “signs coming out of HQ”.
“ I figure why go forward planning a long new trial without being darn sure funds would be available. “
Ahh, prurisol? Remember that?
“Seems to me that's one thing planners would also need to know before going forward. Leo hasn't mentioned what quarter they may start, hopefully the next update spells it out.
Leo hasn’t mentioned what quarter they MAY start, HOPEFULLY(ha-ha) the next quarter spells it out.
Thank God they are, irregardless of what state they are incorporated in, based in Massachusetts.
I suspect you’re right, based on we’re lead to believe:)6
“So Leo is making a salary.”
A rather hefty salary(excluding options).
He’s owner, chief cook, bottle washer, secretary(phones) . Heck, he could give up anywhere between 500-1000 dollars/week of his own pay(leaving him just shy of 8k/week) to allow him to focus on the important issues facing the company. Why won’t he(it’s been suggested to him) do it.
To date he is in my mind, at best, an over paid secretary/ company spokesman(parrot)
A carton of saltines runs about $3/crt. What’s our sp/cracker?n/m. M::mmm:
Polly want a cracker?
George(Dewey)
I believe LR very recently addressed your partial company quote, which you preceded and succeeded by dot-dots, ergo dashing your claim.
"Oh! What A Tangled Web We Weave When First We Practice To Deceive".
Seems as likely as P is worth 15 Billion, etc, ec.
Not all the way there, yet, but leaning that way, as HQ steers us as their messages have conveyed.
Agree, good post.
"What everyone is missing is the real connecting of the dots. It’s quite unfortunate IPIX is on the OTC. It has given a private company the ability to try and destroy their competitor with means of OTC tricks and some proxies. Do some DD, do some tech savvy snoops and you’ll be able to see why the negative interest exists here and why the “non shareholders” know so much about the science of two drugs looking for the same wide open market. It’s pretty simple."
I don't know if it's unfortunate(in managements mind) to be on the otc. The quote below by the cfo/ceo was made over 5 years ago.
"As such, we have shifted our development strategy with our anti-psoriasis drug, Prurisol, to forego the planned Proof-of-Concept trial overseas and have already begun preparing the regulatory paperwork for the Food and Drug Administration to initiate a larger-scale, Phase 2/3 multi-center trial. The adjustment will save us hundreds of thousands of dollars and months of time that will now be better served to position us to potentially have up to five clinical trials ongoing in 2014. This acquisition dovetails very nicely in our goals to continue to build shareholder value and uplist to a senior exchange in the near future."
ph 2/3 P trial- missed it that much
5 clinical trials in 2014- missed it that much
uplist to a senior exchange in the near future- missed by a mile. There's always tomorrow!
I see no correlation to ipix's gutter situation. Please, connect the dots for me, and everyone else.
Sadly, I appreciate your humor, but do hope the company's statements are not guised by "forward looking statements", and are truthful(as I perceive). Massachusetts is the wrong place to rely upon forward looking statements when not being honest.
"If it can make may eyes see $11 a share instead of .11, it's a miracle drug."
A 9900% return! We've declined ~98% in one of the best bull markets ever, but who knows?
LR,
Their approach appears to be the same, regardless of prior successful trials.
P: "Great results" with P-2a, but lets modify a bit and run a P-2b at higher dosage(tic-toc, $$$$(salaries, operating expends))- which failed. Oh well.
B-OM: Great results with swish and spit, but lets modify and use sachets(tic-toc, $$$$(salaries, operating expends)). Hope for the best.
K: Encouraging results, lets modify and go for an oral formulation(tic-toc, $$$$(salaries, operating expends)).
I just wish they had enough dough to hire a qualified secetary/office administrator knowledgable enough to speak for the company, to certain limits, and allow the big wigs to focus on the primary task(s). Used to be a Katherine Gibbs school close by.
The way this company is structured(LE as cheif cook and bottle washer), alot appears to have slipped, including answering the listed phone number. Maybe that's why there is no deal yet?
IDK
They(ipix) stated P endpoints were met, however, they did not release the results enumerating the successes/failures/ae's and sae's as per fda/clinicaltrials protocol.
Perhaps you know the specifics which the rest of us don't?
https://clinicaltrials.gov/ct2/show/NCT02949388?term=innovation+pharmaceuticals&rank=3
Heading toward blue sky territory- all we need is a little push. I think this is LE and AB at the Beverly draw bridge.
" I told Leo to invest Dr Ms salary to hiring some PR. Every new eye with factual info is good."
He need not hire "some pr", Baystreet I assume your referring to. Did ipix/ctix/he(LE)) pay the Boston Business Journal(BBJ) to run those 3 stories? I think not. Check with Don Seiffert of the BBJ or
Max Stendahl of the same periodical. Both have written, within the past two to three years of the grand potential.
They've been made aware of the progress but must be too busy to follow up.
Thank God for investor's, the guy from Queens settled in Boston. Oops for him? Time will tell.
"Now to figure out Verizon. And their move!"
You not know what has been forwarded to separated accounts. Boston Tech, gotta love it.
I've often wondered about a couple ipix "facts';, or statements.
LEO EHRLICH
Co-Founder, CEO, CFO, Board Chairman
• >25 years of executive leadership experience in building and managing emerging
growth companies- Please continue(describe)!
• Multiple C-suite roles at private and public companies-Please continue or describe!
ARTHUR P BERTOLINO, MD, PHD, MBA
President and CMO
• >15 years of domestic and global drug development and management experience
• Extensive senior leadership (VP of Dermatology at Novartis)
15 years of extensive experience. He's 63 years old. 63-15
= 48 years old. What did he do from ~48 y.o to 22 y.o ?
I consider Sonis a parrot. He gets paid to speak(google oral mucositis/stephen sonis). Poly want a cracker($$$).
Curious minds want to know.
Are you suggesting they are moving forward with "insufficient data"? I would argue the opposite.
Please, explain.
"Insufficient data rings to me. But, they're moving forward."
Mom,
Can I borrow $10 to buy 100 shares of a knock out stock?
Per an old commercial for cany bars (Mounds and almond joy),sometimes you feel like a nut, sometimes you don't....
Comments from the principle investigators from the previously completed Prurisol Phase 2a trial:
Quote:
Investigator Comments
Cellceutix would also like to share some observations and comments from Principle Investigators (PIs) overseeing different participating clinical sites in the trial. Numerous PIs noted patients expressed a desire to have access to Prurisol following the study's conclusion. Moreover, the Company learned that some patients were previously unsuccessfully treated with other therapies, including biologics and apremilast (Otezla®).
Included below is a sampling of responses that were authorized to be published:
"Well designed study, patients were pleased, minimal to no side effects."
"Good tolerability was shown with very few AEs reported. Good compliance and good patient satisfaction."
"Overall impression of the study is very positive, as well as the patients' satisfaction."
When asked, "Why would you choose Prurisol (should it be approved) over another oral compound for psoriasis?" and "Why would you choose Prurisol over an injectable biologic?" responses included:
"Because [Prurisol] does not cause any severe side effects. Patients dislike needles and injections because they cause pain and discomfort."
"Patients overall prefer oral medications over injectable medication. Our experience with injectable studies for other indications has been that many subjects do not like taking them and those studies tend to be difficult compared to oral medications to recruit subjects."
"Because of [Prurisol's] low side effect profile."
"Patients prefer oral treatments"
Huh?
Thanks Karin.
Why would it not be transferred to ctix, or ipix's name. Why is it still labeled under Polymedix(if they are non-existatant) and not transferred?
Just curious.
Thx for your response.
Empirics1,,
You state, in part, "Why are you writing off the successful 2b for B for ABSSSI uses, ....
Why is the phase 2b trial you noted not acknowledged by clinicaltrials.gov? Where was the trial administered, and what agency knows the specifics, and who, other than ipix, can corroborate company statements of success?
2 participants. There were adverse events, but no serious adverse events.
From the the bottom of page 7/top of page 8 in the link attached below.
"A serious adverse event (experience) or reaction is any untoward
medical occurrence that at any dose:
Results in death,
Is life-threatening,
NOTE: The term "life-threatening" in the definition of
"serious" refers to an event in which the patient was at risk
of death at the time of the event; it does not refer to an
event which hypothetically might have caused death if it
were more severe.
Requires inpatient hospitalization or prolongation of existing
hospitalization,
Results in persistent or significant disability/incapacity, or
Is a congenital anomaly/birth defect."
https://www.fda.gov/downloads/drugs/guidances/ucm073087.pdf
Results of Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer posted today on clinicaltrials site.
https://clinicaltrials.gov/ct2/show/results/NCT03042702?term=innovation+pharmaceuticals&rank=1
slcimmuno,
Thanks for that post. Very informative.
"It seems, IPIX is planning for a busy future where they will put the space to good use."
That's my hope as well as I can't imagine someone forgot to inform Cummings Properties six months prior to 9/30/18 that ipix would not be renewing the lease.
"Menon separated KARD from CTIX when he moved KARD’s work out of Beverly, and CTIX acquired the equipment and all IP along with Brilacidin."
Where did KARD relocate to?
....."will they take risk of investing in a company with a CEO with minimum credibility and issues PR that tread on thin line between misinformation and lying."
I don't think so. Much like Gen. Mattis spat on Trumps shoes, so to speak.
Fight your own battles is, to me, what Mattis effectively told our President. I believe many long term ipix investors question the Lion's(Leo) wisdom.
https://www.businessinsider.com/james-mattis-quotes-2018-3
"...;our management just doesn't get the benefit of the doubt after the Prurisol failure....."
Based on the following, they had not received the benefit of doubt prior to the recently announced P failure.
week of 12/15/14, closing price= 4.375
week of 12/14/15, closing price= 1.40,$^=(2.97), %^ (68%) tot%^(68%)
week of 12/12/16, closing price=1.26, $^=(0.16), %^ (10%) tot%^(71%)
week of 12/18/17, closing price=0.71, $^=(0.55), %^ (56%) tot%^(84%)
week of 12/17/18, closing price=0.097,$^=(.613), %^ (76%) tot%^(98%)
Note, closing price is the closing price of the noted weeks. We have one more day to go for this week(12/17/18).
$^ is the the difference in closing share price from the year earlier.
%^ is the percentage change in closing price from a year earlier.
tot%^ is the percentage change in closing price since the closing price of week 12/15/14.
Not sure what they can do other than alter course(hopefully with a deal announcement)- pronto.
"The big ticket is who's going to pay for it. We're stuck till that comes out."
We haven't been stuck, we've been sliding down a long time.
week of 12/15/14, closing price= 4.375
week of 12/14/15, closing price= 1.40,$^=(2.97), %^ (68%) tot%^(68%)
week of 12/12/16, closing price=1.26, $^=(0.16), %^ (10%) tot%^(71%)
week of 12/18/17, closing price=0.71, $^=(0.55), %^ (56%) tot%^(84%)
week of 12/17/18, closing price=0.097,$^=(.613), %^ (76%) tot%^(98%)
Note, closing price is the closing price of the noted weeks. We have one more day to go for this week(12/17/18).
$^ is the the difference in closing share price from the year earlier.
%^ is the percentage change in closing price from a year earlier.
tot%^ is the percentage change in closing price since the closing price of week 12/15/14.
Hopefully they sign a deal of some sort.
They're also in the middle of the second cycle for the K trial results review.
Cycle 1 to clinicaltrials.gov 11/6/18, results returned 12/4/18.
Cycle 2 to clinicaltrials.gov 12/5/18, return pending
"Who has the most to lose?" It's neither any of the Ehrlich's or Menon's, that's for sure. They've been paid handsomely over the years and shelled out not a cent for any of their millions of shares.